Introduction
============

The cardiovascular disease burden worldwide is highly influenced by the major risk factor of hypertension ([@b1-etm-0-0-4412]). Hypertension is a pathological state responsible for sudden death, stroke, coronary heart disease, heart failure, auricular fibrillation, peripheral vascular disease, and renal insufficiency ([@b2-etm-0-0-4412],[@b3-etm-0-0-4412]). In China, the number of positive patients with hypertension is more than 330 million and in every 3 adults, there is one with hypertension ([@b4-etm-0-0-4412],[@b5-etm-0-0-4412]). The major causative factor responsible for this is a high salt diet and salt sensitivity ([@b6-etm-0-0-4412]). Salt sensitivity is basically a clinical observation of alterations in blood pressure of the patient with respect to his/her salt intake ([@b7-etm-0-0-4412]). Moreover, salt sensitive individuals are also affected by endothelial dysfunction, which may be an important contributor of cardiovascular risks of salt sensitive hypertension ([@b8-etm-0-0-4412]).

Resistant hypertension is the extreme pathological state wherein more than four mediations including diuretic are engaged in order to control blood pressure ([@b9-etm-0-0-4412]). A diuretic is an indispensable antihypertensive drug utilized worldwide for the treatment of hypertension ([@b10-etm-0-0-4412]). However, a long-term large-dose administration of diuretics would affect the glucose, lipid metabolism and electrolyte; thus, its role as a first-line antihypertensive drug is limited to some extent. Consequently, the selection of an effective diuretic as well as proper dose is crucial in these cases. Moreover, there is no scientific evidence in evidence-based medicine as to how to choose proper and effective diuretics, especially in the cases of resistant hypertension.

The present study investigated the influences of different diuretics on pressure-natriuresis curves of resistant hypertension patients, in order to provide a research basis for improving the individualized new drug and non-drug therapies for resistant hypertension.

Materials and methods
=====================

### Experimental grouping

A cohort of 23 patients with non-hypertension (NH) (13 males and 10 females; aged 23--62 years), 26 patients with controlled hypertension (CH) (14 males and 12 females; aged from 19 to 72 years) and 23 patients with RH (13 males and 10 females; aged from 19 to 76 years) were selected. Salt sensitivity was measured by utilizing acute/chronic salt load tests. According to the salt sensitive index (SSI) the patients were segregated into two groups viz. salt sensitive (SS) and non-SS (NSS) groups. The two groups were further classified into four subgroups based on the diuretic drug used. Hydrochlorothiazide-treated subgroups were termed SS hydrochlorothiazide (SSHy) and non-SSHy (NSSHy) groups. Similarly, triamterene-treated subgroups were designated as SS triamterene (SSTr) and non-SSTr (NSSTr) groups. Patients received oral administration of diuretics for two weeks in high salt diet period. During the chronic salt load test period, the 24-h natriuresis/kaluresis, serum sodium/potassium, cortisol, plasma aldosterone, renin activity, office blood pressure, 24-h ambulatory blood pressure (ABP), pressure pulse waveform (PWA) and carotid-to-femoral pulse wave velocity (PWVcf) at day 7 were monitored during low salt diet period, balanced salt diet period, high salt diet period and diuretic intervention period. Finally, we drew the pressure-natriuresis curve according to the result of chronic salt load test. The radioimmunoassay was applied to detect the plasma aldosterone and renin activity, and SphygmoCor non-invasive arterial pressure wave analyzer was used to detect PWA and PWVcf.

### Requirements of Medical Ethics Committee

This study obtained written informed consents of the enrolled subjects or their family. The study conforms to the Medical Ethics and obtained approval of the Biomedical Research Ethics Committee of the Central Hospital of Xuzhou.

### Screening

Screening and treatment of the possible pathogeny of hypertension was performed by using modern diagnosis and treatment technology to screen and exclude secondary hypertension, including renal parenchyma, renal vascular, primary hyperaldosteronism, sleep apnea syndrome and pheochromocytoma.

### Acute and chronic salt load tests

The improvised short method was used, which included dripping of 2,000 ml normal saline into the patients, which was immediately followed by the administration of 40 mg furosemide. After 2 h, blood pressure was recorded. This was followed by calculation of growth rate between salt load mean pressure and baseline pressure, and the decreasing rate between mean blood pressure (MBP) (2 h after furosemide) and baseline pressure, the sum of the two values ≥15 mmHg was considered to be salt sensitive. On the other hand, a decreasing rate \<5 mmHg was considered to be salt resistive.

### Chronic salt load test

Combining the methods of American Nutrition Society 2010 Yatabe and the method proposed by Dr Mou Jianjun under the reference of Jackson 2003 ([@b11-etm-0-0-4412],[@b12-etm-0-0-4412]): Balanced diet (9 g/day, 150 mmol/day Na) × 7 days, 3 g salt in each meal viz. breakfast, lunch and dinner each; then low salt diet (3 g/day, 51.3 mmol/day Na^+^) × 7 days, 1 g salt in each meal viz. breakfast, lunch and dinner each; immediately followed by high salt diet (18 g/day, 307.7 mmol/day Na^+^) × 7 days, 3 g salt for breakfast and 7.5 g salt for lunch and dinner. We monitored the 24 h ABP, office blood pressure, aldosterone, 24 h natriuresis, 24 h kaliuresis, PWA and PWV. Salt sensitivity was calculated by finding the SSI according to MBP in low salt period and high salt period. SSI = (MBPHs - MBPLs)/MBPLs, SSI \>5% was considered to be SS; where SSI \<5% was considered to be salt resistant (SR). According to the SSI, the subjects were divided into SS and non-SS (NSS) groups. Then according to complete random design, the patients were further divided into with hypertension salt sensitivity and hypertension non-salt sensitivity into SSHy, SSTr, NSSHy and NSSTr groups. Patients received oral administration of diuretic for two weeks in high salt diet period. During chronic salt load test period, we monitored the 24 h natriuresis/kaluresis, serum sodium/potassium, cortisol, plasma aldosterone, renin activity, office blood pressure, 24 h ABP, PWA and PWVcf at day 7 during low salt diet period, balanced salt diet period, high salt diet period and diuretic intervention period. Then the pressure-natriuresis curve was drawn based on the results of chronic salt load test.

### Radioimmunoassays and other immune assays

All the radioimmunoassays and other immune assays were performed by the specific kits as per the supplier protocols.

Results
=======

### Screening results of resistant hypertension

From October 2012 to October 2014, a total of 593 patients received hypertension screening and treatment in the Central Hospital of Xuzhou, among whom were 62 cases (10.46%) of resistant hypertension. In the above 62 patients, 55 patients were admitted to hospital and received diagnostic classification and had comprehensively individualized treatment. In the 55 admitted patients, 28 patients (50.90%) were diagnosed with essential resistant hypertension, 12 (21.82%) with essential aldosteronism, 5 (9.09%) with obstructive sleep apnea syndrome, 3 (5.45%) with renal parenchymal hypertension, 5 (9.09%) with renal vascular hypertension (4 atherosclerosis and 1 fibromuscular dysplasia), 1 (1.82%) with Cushing\'s syndrome, 1 (1.82%) with chromaffinoma, and 0 with aortic constriction, 0 with drug-induced hypertension.

### Results of acute salt load test

After the acute salt load test, 7 of 16 cases in the NH group were confirmed with salt sensitivity, and the detection rate was 43.75%; 10 of 20 cases in the CH group were confirmed with salt sensitivity, and the detection rate was 50.00%; 8 of 19 cases in the RH group were confirmed with salt sensitivity, with a detection rate of 42.11% ([Table I](#tI-etm-0-0-4412){ref-type="table"}).

### Results of chronic salt load test

After the chronic salt load test, 7 of 16 cases in the NH group were confirmed with salt sensitivity, detection rate of 43.75%; 11 of 20 cases in CH group were confirmed with salt sensitivity, detection rate of 55.00%; and 8 of 19 cases in RH group were confirmed with salt sensitivity, with a detection rate of 47.37% (P\>0.05) ([Table II](#tII-etm-0-0-4412){ref-type="table"}).

### Results of diuretic intervention trial

The NH group received 3-week chronic salt load test, RH and CH groups received 5-week chronic salt load test and diuretic intervention trial. Differences in plasma aldosterone, renin activity, office blood pressure (systolic blood pressure, diastolic blood pressure, mean arterial pressure), 24 h ABP, central aortic pressure, and carotid pulse wave conduction velocity among the three groups were observed to be statistically different (P\<0.05). The results confirmed the ability of diuretics to change the right shift of the pressure-natriuresis curve ([Figs. 1](#f1-etm-0-0-4412){ref-type="fig"}--[3](#f3-etm-0-0-4412){ref-type="fig"} and [Table III](#tIII-etm-0-0-4412){ref-type="table"}).

Discussion
==========

Resistant hypertension is a particular type of hypertension characterized by high baseline, long course, and many combined risk factors ([@b13-etm-0-0-4412]). Management of this deadly pathological state involved utilization of 3--4 antihypertensive drugs including diuretics, so as to get the blood pressure of affected patient to normal ([@b14-etm-0-0-4412],[@b15-etm-0-0-4412]). However, random employment of diuretics in the management of this pathological state may result in the obstruction of the epithelial sodium channels or reduce the re-absorption of Na^+^ and Cl^−^ ([@b16-etm-0-0-4412]). Sensitivity to salt is another key player influencing the use of diuretic therapeutics in resistant hypertension ([@b7-etm-0-0-4412],[@b17-etm-0-0-4412]). Salt sensitivity is the key player that helps in achieving resistance to the treatment during resistant hypertension. In the present study, modulatory potential of two antihypertensive drugs, the triamterene and hydrochlorothiazide, have been studied in resistive hypertension patients.

Triamterene is a water pill that has the ability to control the salt absorption by the body and simultaneously keeps the potassium levels in the normal range ([@b18-etm-0-0-4412]). It does this by blocking the sodium channels ([@b19-etm-0-0-4412]). On the other hand, hydrochlorothiazide is a thiazide medication able to cause decline in the retention of water by kidneys ([@b20-etm-0-0-4412]). The combination of these two drugs in the present study, successfully managed resistant hypertensions by resulting in significant improvement in water-sodium retention in the affected patients. Moreover, in the present study, the mechanism of the therapeutic effects of this combination was further studied in a novel way by observation of the pressure-natriuresis curve.

Pressure-natriuresis curve has the ability to show an increase of the resistance of afferent glomerular arteriole, the glomerulotubular imbalance and the increase of sodium reabsorption of kidney tubules. In the present study, salt intake constant deduced from pressure-natriuresis curve indicated the blood pressure sensitivity to salt, which also provided a new hypothesis for the study of the salt sensitivity mechanism ([@b21-etm-0-0-4412]). The urine protein excretion rate of the SS group has been observed to be significantly higher than that of the non-SS group, which directly related the urine protein excretion rate to increasing glomerular capillary pressure ([@b22-etm-0-0-4412]).

Thus, it is evident from the above observations that the combination of drugs is able to efficiently manage resistant hypertension as indicated by the information recorded in the pressure-natriuresis curve. Use of pressure-natriuresis to check salt sensitivity in patients is a good hypothesis for selecting individual combination of antihypertensive drugs for more efficient treatments with minimal side effects. However, more studies are required in the clinical settings making this approach the gold standard in resistant hypertension patients.

This study was partly financed by the Jiangsu Provincial Special Program of Medical Science (BL2012019).
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###### 

Result of acute salt load test result.

  Groups   Case   SS detection rate (%)
  -------- ------ -----------------------
  NH       16     43.75
  CH       20     50.00
  RH       19     42.11

NH, non-hypertension; CH, controlled hypertension; RH, resistant hypertension.

###### 

Result of chronic salt load test result.

  Groups   Case   SS detection rate (%)
  -------- ------ -----------------------
  NH       16     43.75
  CH       20     55.00
  RH       19     47.37

NH, non-hypertension; CH, controlled hypertension; RH, resistant hypertension.

###### 

Indexes related to chronic salt loading test and diuretic intervention in each group.

  Items                      RH ([@b19-etm-0-0-4412])   CH ([@b20-etm-0-0-4412])   NH ([@b16-etm-0-0-4412])   P-value
  -------------------------- -------------------------- -------------------------- -------------------------- ---------
  24 h UNa ls                66.88±23.23                66.38±26.72                58.80±17.41                P\>0.05
  24 h UNa ms                167.66±38.96               162.39±27.18               160.81±23.95               P\>0.05
  24 h UNa hs                297.61±56.55               316.40±62.04               300.80±37.38               P\>0.05
  24 h UNa hs1               297.99±90.56               313.66±79.32                                          P\>0.05
  24 h UNa ms2               184.97±39.56               190.01±48.27                                          P\>0.05
  24 h urine potassium ls    58.32±38.60                63.56±14.28                49.46±25.36                P\>0.05
  24 h urine potassium ms    66.98±43.60                62.17±23.89                56.10±34.85                P\>0.05
  24 h urine potassium hs    65.04±29.59                71.09±20.51                50.24±26.18                P\>0.05
  24 h urine potassium hs1   69.61±45.79                67.56±24.95                                           P\>0.05
  24 h urine potassium ms2   65.25±23.87                64.60±19.79                                           P\>0.05
  Serum Na^+^ ls             138.91±3.10                139.14±1.78                131.19±32.69               P\>0.05
  Serum Na^+^ ms             132.84±31.31               1.40.70±2.71               139.51±1.79                P\>0.05
  Serum Na^+^ hs             139.82±2.20                143.47±30.56               140.17±2.20                P\>0.05
  Serum Na^+^ hs1            132.23±1.25                133.28±30.52                                          P\>0.05
  Serum Na^+^ ms2            140.00±3.13                139.86±2.16                                           P\>0.05
  Serum K^+^ ls              4.28±0.25                  4.4±0.22                   4.11±0.32                  P\>0.05
  Serum K^+^ ms              4.21±0.13                  4.26±0.35                  4.23±0.23                  P\>0.05
  Serum K^+^ hs              4.16±0.25002               4.12±0.31                                             P\>0.05
                             4.10±0.30                                                                        
  Serum K^+^ hs1             4.11±0.30                  4.00±0.32                                             P\>0.05
  Serum K^+^ ms2             4.34±0.43860               4.18±0.21                                             P\>0.05
  Aldols                     359.61±93.70               349.38±28.46               390.21±59.50               P\<0.05
  Aldoms                     272.41±98.26               269.75±74.15               285.77±133.33              P\<0.05
  Aldohs                     171.17±91.51               166.72±79.31               157.51±81.32               P\<0.05
  Aldohs1                    311.65±.92                 240.94±97.28                                          P\<0.05
  Aldoms2                    263.71±72.81               278.92±123.98                                         P\<0.05
  Reninls                    2.97±4.74                  1.45±1.62                  7.18±2.11                  P\<0.05
  Reninms                    1.24±1.39                  0.57±0.61                  1.26±1.78                  P\<0.05
  Reninhs                    0.64±0.977                 0.26±0.28                  0.47±0.354                 P\<0.05
  Reninhs1                   1.89±2.12                  0.68±0.69                                             P\<0.05
  Reninms2                   2.14±3.34                  1.12±0.80                                             P\<0.05
  SBPobpmls                  135.68±14.87               128.80±13.48               118.41±9.97                P\<0.05
  DBPobpmls                  81.16±11.46                73.05±9.87                 72.24±7.00                 P\<0.05
  MBPobpmls                  99.33±11.56                91.63±9.84                 87.62±7.52                 P\<0.05
  SBPobpmms                  143.26±14.83               133.10±11.09               120.06±9.743               P\<0.05
  DBPobpmms                  88.89±11.827               76.15±9.810                71.29±5.49                 P\<0.05
  MBPobpmms                  107.02±12.18               87.54±5.74                 87.54±5.74                 P\<0.05
  SBPobpmhs                  142.21±9.63                133.95±9.976               123.29±6.96                P\<0.05
  DBPobpmhs                  85.95±9.113                76.15±10.00                74.41±5.94                 P\<0.05
  MBPobpmhs                  104.70±8.27                95.41±8.99                 90.705±5.37                P\<0.05
  SBPobpmhs1                 141.95±16.708              133.3±10.22                                           P\<0.05
  DBPobpmhs1                 84.84±15.178               74.11±9.06                                            P\<0.05
  MBPobpmms2                 103.88±14.38930            93.84±7.46                                            P\<0.05
  SBPobpmls                  139.00±18.12               130.47±8.72                                           P\<0.05
  DBPobpmms2                 77.95±10.648               72.89±7.42                                            P\>0.05
  MBPobpmms2                 98.29±12.18626             92.08±6.46                                            P\<0.05
  SBPabpmls                  138.32±17.12               129.35±14.324              127.29±11.389              P\>0.05
  DBPabpmls                  85.42±12.02                76.05±8.79                 74.12±6.52                 P\>0.05
  MBPabpmls                  103.05±13.30518            93.81±9.98                 91.84±7.53                 P\>0.05
  SBPabpmms                  142.79±15.76               138.10±13.90               125.76±9.19                P\>0.05
  DBPabpmms                  87.05±10.71                79.45±5.85                 75.12±6.48                 P\>0.05
  MBPabpmms                  105.63±11.57               99.00±7.75                 92.00±7.05                 P\<0.05
  SBPabpmhs                  143.37±14.72               144.05±12.57               121.59±8.38                P\>0.05
  DBPabpmhs                  86.00±12.12                81.85±7.06                 71.94±4.61                 P\<0.05
  MBPabpmhs                  105.12±12.39               102.58±7.84                88.49±5.77                 P\>0.05
  SBPabpmhs1                 143.58±17.734              138.05±10.14                                          P\>0.05
  DBPabpmhs1                 88.05±12.04                81.20±7.79                                            P\>0.05
  MBPabpmmhs1                106.56±13.23               100.15±7.74                                           P\>0.05
  SBPabpmms2                 140.68±19.17               134.75±10.43                                          P\>0.05
  DBPabpmms2                 84.05±11.02                78.90±7.290                                           P\>0.05
  MBPabpmms2                 102.93±13.00               97.51±7.51                                            P\>0.05
  PWASBPls                   128.82±16.21               119.35±13.09               108.18±9.16                P\<0.05
  PWASBPms                   132.24±14.53               123.30±11.29               107.65±9.13                P\<0.05
  PWASBPhs                   123.94±10.61               124.05±11.82               105.29±6.743               P\<0.05
  PWASBPhs1                  133.88±14.85               123.21±10.26                                          P\<0.05
  PWASBPms2                  126.94±14.355              120.05±7.70                                           P\<0.05
  PWVcfls                    9.91±1.30                  9.06±2.29                  7.11±1.431                 P\<0.05
  PWVcfms                    10.11±1.89                 9.90±2.08                  7.38±1.33                  P\<0.05
  PWVcfhs                    11.71±1.78                 10.98±2.219                8.10±1.41                  P\<0.05
  PWVcfhs1                   9.8±1.89                   9.67±1.63                                             P\>0.05
  PWVcfms2                   10.60±3.02                 9.84±1.48                                             P\>0.05

RH, resistant hypertension; CH, controlled hypertension; NH, non-hypertension.
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